DK2950795T3 - Fremgangsmåde til behandling og heling af leishmaniose under anvendelse af fexinidazol - Google Patents
Fremgangsmåde til behandling og heling af leishmaniose under anvendelse af fexinidazol Download PDFInfo
- Publication number
- DK2950795T3 DK2950795T3 DK14705908.3T DK14705908T DK2950795T3 DK 2950795 T3 DK2950795 T3 DK 2950795T3 DK 14705908 T DK14705908 T DK 14705908T DK 2950795 T3 DK2950795 T3 DK 2950795T3
- Authority
- DK
- Denmark
- Prior art keywords
- fexinidazole
- leishmania
- treatment
- dogs
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Fexinidazol til anvendelse i behandling afen Leishmania infantum-infektion i et hunde-dyr, hvor hunden ikke lider af tilbagefald i mindst tredive dage efter fexinidazolbehandling.
2. Fexinidazol til anvendelse ifølge krav 1, hvor den administrerede mængde fexinidazol er tilstrækkelig til at tilvejebringe en fexinidazolplasmakoncentration der overstiger 10 ng/ml i mindst 1 time under hver dag i løbet af et fexinidazoladministrationsforløb.
3. Fexinidazol til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den administrerede mængde fexinidazol er tilstrækkelig til at tilvejebringe en fexinidazolplasmakoncentration der overstiger 30 ng/ml i mindst 2 timer dagligt.
4. Fexinidazol til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den administrerede mængde fexinidazol er tilstrækkelig til at tilvejebringe en fexinidazolplasmakoncentration der er større end 60 ng/ml i mindst et tidspunkt dagligt.
5. Fexinidazol til anvendelse ifølge et hvilket som helst af de foregående krav, hvor fexinidazol administreres oralt i løbet af mindst tyve dage.
6. Fexinidazol til anvendelse ifølge et hvilket som helst af de foregående krav, hvor fexinidazol administreres i mindst otteogtyve dage.
7. Fexinidazol til anvendelse ifølge et hvilket som helst af de foregående krav, hvor fexinidazol mikroniseres og opslæmmes i en opløsning afvand og DMSO.
8. Fexinidazol til anvendelse ifølge et hvilket som helst af de foregående krav, hvor hunden ikke lider af tilbagefald i mindst 180 dage efter fexinidazolbehandling.
9. Fexinidazol til anvendelse ifølge et hvilket som helst af de foregående krav, hvor fexinidazol metaboliseres til fexinidazolsulfon og/eller fexinidazolsulfoxid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361758918P | 2013-01-31 | 2013-01-31 | |
PCT/US2014/014134 WO2014121064A1 (en) | 2013-01-31 | 2014-01-31 | Method for treating and curing leishmaniosis using fexinindazole |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2950795T3 true DK2950795T3 (da) | 2018-07-30 |
Family
ID=50151374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14705908.3T DK2950795T3 (da) | 2013-01-31 | 2014-01-31 | Fremgangsmåde til behandling og heling af leishmaniose under anvendelse af fexinidazol |
Country Status (17)
Country | Link |
---|---|
US (1) | US9585871B2 (da) |
EP (1) | EP2950795B1 (da) |
AU (1) | AU2014212217B2 (da) |
CY (1) | CY1120381T1 (da) |
DK (1) | DK2950795T3 (da) |
ES (1) | ES2681420T3 (da) |
HK (1) | HK1211466A1 (da) |
HR (1) | HRP20181181T1 (da) |
HU (1) | HUE039467T2 (da) |
IL (1) | IL240246B (da) |
LT (1) | LT2950795T (da) |
MX (1) | MX367952B (da) |
PL (1) | PL2950795T3 (da) |
PT (1) | PT2950795T (da) |
RS (1) | RS57469B1 (da) |
SI (1) | SI2950795T1 (da) |
WO (1) | WO2014121064A1 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102403531B1 (ko) * | 2016-04-06 | 2022-05-27 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 거울상 이성질체적으로 풍부한 이속사졸린 화합물의 제조 방법 및 (s)-아폭솔라너의 결정질 톨루엔 용매화물 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4914624A (da) | 1972-06-08 | 1974-02-08 | ||
US3950360A (en) | 1972-06-08 | 1976-04-13 | Sankyo Company Limited | Antibiotic substances |
SE434277B (sv) | 1976-04-19 | 1984-07-16 | Merck & Co Inc | Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis |
US4134973A (en) | 1977-04-11 | 1979-01-16 | Merck & Co., Inc. | Carbohydrate derivatives of milbemycin and processes therefor |
US4199569A (en) | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
US4144352A (en) | 1977-12-19 | 1979-03-13 | Merck & Co., Inc. | Milbemycin compounds as anthelmintic agents |
US4203976A (en) | 1978-08-02 | 1980-05-20 | Merck & Co., Inc. | Sugar derivatives of C-076 compounds |
JPS57139012A (en) | 1981-02-23 | 1982-08-27 | Sankyo Co Ltd | Anthelmintic composition |
US4427663A (en) | 1982-03-16 | 1984-01-24 | Merck & Co., Inc. | 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof |
EP0237482A1 (de) | 1986-03-06 | 1987-09-16 | Ciba-Geigy Ag | C(29)-Carbonyloxi-milbemycin-Derivate zur Bekämpfung von tier- und pflanzenparasitären Schädlingen |
RU2024527C1 (ru) | 1986-03-25 | 1994-12-15 | Санкио Компани Лимитед | Способ получения макролидных соединений |
EP0252879B1 (de) | 1986-07-02 | 1992-05-06 | Ciba-Geigy Ag | Pestizide |
US4855317A (en) | 1987-03-06 | 1989-08-08 | Ciba-Geigy Corporation | Insecticides and parasiticides |
US4871719A (en) | 1987-03-24 | 1989-10-03 | Ciba-Geigy Corporation | Composition for controlling parasites in productive livestock |
US4874749A (en) | 1987-07-31 | 1989-10-17 | Merck & Co., Inc. | 4"-Deoxy-4-N-methylamino avermectin Bla/Blb |
EP0319142B1 (en) | 1987-11-03 | 1994-04-06 | Beecham Group Plc | Intermediates for the preparation of anthelmintic macrolide antibiotics |
NZ232422A (en) | 1989-02-16 | 1992-11-25 | Merck & Co Inc | 13-ketal milbemycin derivatives and parasiticides |
NZ247278A (en) | 1991-02-12 | 1995-03-28 | Ancare Distributors | Veterinary anthelmintic drench comprising a suspension of praziquantel in a liquid carrier |
US5345377A (en) | 1992-10-30 | 1994-09-06 | Electric Power Research Institute, Inc. | Harmonic controller for an active power line conditioner |
GB9300883D0 (en) | 1993-01-18 | 1993-03-10 | Pfizer Ltd | Antiparasitic agents |
AUPM969994A0 (en) | 1994-11-28 | 1994-12-22 | Virbac S.A. | Equine anthelmintic formulations |
IE80657B1 (en) | 1996-03-29 | 1998-11-04 | Merial Sas | Insecticidal combination to control mammal fleas in particular fleas on cats and dogs |
US6010710A (en) | 1996-03-29 | 2000-01-04 | Merial | Direct pour-on skin solution for antiparasitic use in cattle and sheep |
FR2752525B1 (fr) | 1996-08-20 | 2000-05-05 | Rhone Merieux | Procede de lutte contre les myiases des cheptels bovins et ovins et compositions pour la mise en oeuvre de ce procede |
US5885607A (en) | 1996-03-29 | 1999-03-23 | Rhone Merieux | N-phenylpyrazole-based anti-flea and anti-tick external device for cats and dogs |
US6998131B2 (en) | 1996-09-19 | 2006-02-14 | Merial Limited | Spot-on formulations for combating parasites |
US6174540B1 (en) | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
CU23506B6 (es) * | 2005-09-26 | 2010-04-13 | Ct Bioactivos Quimicos Univers | Composiciones farmacéuticas que contienen derivados nitrovinilfuránicos para el tratamiento de la leishmaniosis y la tripanosomosis |
PT103503B (pt) * | 2006-06-19 | 2009-05-18 | Univ Do Porto | Novos derivados do bisnaftalimidopropil, processo para a sua preparação, composições farmacêuticas que os contêm e sua utilização em doenças cancerígenas e parasitárias, nomeadamente leishmanioses, tripanossomíases e malária. |
PL2035390T3 (pl) | 2006-07-05 | 2016-06-30 | Merial Inc | Związki będące pochodnymi 1-arylo-5-alkilopirazolu, sposoby ich wytwarzania i zastosowania |
MD20170009A2 (ro) | 2012-02-06 | 2017-07-31 | Merial Limited | Compoziţii veterinare antiparazitare orale cu conţinut de agenţi activi cu acţiune sistemică, metode şi aplicări ale acestora |
-
2014
- 2014-01-31 WO PCT/US2014/014134 patent/WO2014121064A1/en active Application Filing
- 2014-01-31 AU AU2014212217A patent/AU2014212217B2/en active Active
- 2014-01-31 MX MX2015009907A patent/MX367952B/es active IP Right Grant
- 2014-01-31 HU HUE14705908A patent/HUE039467T2/hu unknown
- 2014-01-31 PL PL14705908T patent/PL2950795T3/pl unknown
- 2014-01-31 SI SI201430743T patent/SI2950795T1/en unknown
- 2014-01-31 RS RS20180840A patent/RS57469B1/sr unknown
- 2014-01-31 US US14/169,713 patent/US9585871B2/en active Active
- 2014-01-31 PT PT147059083T patent/PT2950795T/pt unknown
- 2014-01-31 EP EP14705908.3A patent/EP2950795B1/en active Active
- 2014-01-31 LT LTEP14705908.3T patent/LT2950795T/lt unknown
- 2014-01-31 ES ES14705908.3T patent/ES2681420T3/es active Active
- 2014-01-31 DK DK14705908.3T patent/DK2950795T3/da active
-
2015
- 2015-07-30 IL IL240246A patent/IL240246B/en active IP Right Grant
- 2015-12-11 HK HK15112231.7A patent/HK1211466A1/xx unknown
-
2018
- 2018-07-03 CY CY20181100687T patent/CY1120381T1/el unknown
- 2018-07-24 HR HRP20181181TT patent/HRP20181181T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
SI2950795T1 (en) | 2018-07-31 |
MX367952B (es) | 2019-09-12 |
WO2014121064A1 (en) | 2014-08-07 |
ES2681420T3 (es) | 2018-09-13 |
US9585871B2 (en) | 2017-03-07 |
HK1211466A1 (en) | 2016-05-27 |
PL2950795T3 (pl) | 2018-09-28 |
MX2015009907A (es) | 2016-03-01 |
AU2014212217A1 (en) | 2015-08-20 |
HRP20181181T1 (hr) | 2018-10-19 |
HUE039467T2 (hu) | 2019-01-28 |
IL240246B (en) | 2019-03-31 |
US20140213624A1 (en) | 2014-07-31 |
EP2950795B1 (en) | 2018-04-25 |
IL240246A0 (en) | 2015-09-24 |
CY1120381T1 (el) | 2019-07-10 |
AU2014212217B2 (en) | 2016-11-10 |
EP2950795A1 (en) | 2015-12-09 |
PT2950795T (pt) | 2018-07-30 |
RS57469B1 (sr) | 2018-09-28 |
LT2950795T (lt) | 2018-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102560198B1 (ko) | 이속사졸린 활성제를 포함하는 지속형 주사용 제형, 이의 방법 및 용도 | |
EP3277303B1 (en) | Anthelmintic combinations and methods of use thereof | |
SE1751350A1 (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
Meinke | Perspectives in animal health: old targets and new opportunities | |
DK2950795T3 (da) | Fremgangsmåde til behandling og heling af leishmaniose under anvendelse af fexinidazol | |
Tyrrell et al. | Overcoming macrocyclic lactone resistance in Haemonchus contortus with pulse dosing of levamisole | |
US11773066B2 (en) | Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof | |
ZA200604043B (en) | Multiple active agents such as anthelmintics sustained release delivery | |
AU2020208145B2 (en) | Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof | |
US20220202835A1 (en) | Injectable clorsulon compositions, methods and uses thereof | |
EP3096739B1 (en) | Topical delivery formulation | |
US11583545B2 (en) | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof |